|Exchange:||New York Stock Exchange|
|Stock:||Boston Scientific Inc|
|Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties. The Company’s products were offered for sale by seven core businesses - Interventional Cardiology, Cardiac Rhythm Management (CRM), Endoscopy, Peripheral Interventions (PI), Urology and Women’s Health, Neuromodulation, and Electrophysiology (EP). market a broad portfolio of internally-developed and self-manufactured drug-eluting stents including the Promus® Element™ and Promus® Element™ Plus everolimus-eluting stents, as well as its TAXUS® Element™ and Ion™ paclitaxel-eluting stents. The Company sell various products designed to treat patients with peripheral disease (disease which appears in blood vessels other than in the heart and in the biliary tree), including a broad line of medical devices used in percutaneous transluminal angioplasty (PTA) and peripheral vascular stenting. Its peripheral product offerings include stents, balloon catheters, wires, peripheral embolization devices and vena cava filters. Its peripheral angioplasty balloon technology includes its next-generation Mustang™ PTA balloon, its Coyote™ balloon catheter, a deliverable and ultra-low profile balloon dilatation catheter designed for a wide range of peripheral angioplasty procedures, and its Charger™ PTA Balloon Catheter, a 0.035” percutaneous transluminal angioplasty balloon catheter designed for post-stent dilatation as well as conventional balloon angioplasty to open blocked peripheral arteries. The Company also sell products designed to treat patients with non-vascular disease (disease that appears outside the blood system). Its non-vascular suite of products includes biliary stents, drainage catheters and micro-puncture sets designed to treat, diagnose and ease various forms of benign and malignant tumors. The Company continue to market its extensive line of Interventional Oncology product solutions, including the recently launched Renegade® HI-FLO™ Fathom® microcatheter and guidewire system and Interlock™ - 35 Fibered IDC™ Occlusion System for peripheral embolization. The Company develop, manufacture and market a variety of implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, including: Implantable cardioverter defibrillator (ICD), Implantable pacemaker systems. During 2013, the company marketed its products to over 13,000 hospitals, clinics, outpatient facilities and medical offices in approximately 100 countries. The Company is subject to various environmental laws, directives and regulations both in the U.S. and abroad. Its operations, like those of other medical device companies, involve the use of substances regulated under environmental laws, primarily in manufacturing and sterilization processes.|
Copyright © 2014 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.